复宏汉霖:ADC药物HLX43获FDA孤儿药资格认定

财经网
Oct 21

近日,复宏汉霖发布公告称,公司全资子公司HenliusUSAInc.收到美国食品药品管理局(FDA)的函,注射用HLX43(靶向PD-L1抗体偶联药物)用于胸腺上皮肿瘤(TETs)治疗获FDA授予孤儿药资格认定。HLX43是由复宏汉霖利用许可引进的新型DNA拓扑异构酶I抑制剂小分子毒素-肽链连接子与本公司自主研发的靶向PD-L1的抗体进行偶联开发的靶向PD-L1的抗体偶联药物(ADC),拟用于晚期...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10